Pharmacologic Treatment of Eosinophilic Esophagitis: Efficacious, Likely Efficacious, and Failed Drugs

Overview

Journal Inflamm Intest Dis

Date 2024 Oct 30

PMID 39474328

Authors

Alain M Schoepfer

Ekaterina Safroneeva

Affiliations

Soon will be listed here.

Abstract

Background: Eosinophilic esophagitis (EoE) is a chronic, food allergen-mediated, esophageal disease that will lead, if left untreated, to esophageal remodeling. As such, the vast majority of EoE patients need treatment. Treatment strategies include drugs, food elimination diets, and esophageal dilation. This review focuses on pharmacologic options for treatment of EoE.

Summary: Orodispersible budesonide tablets (Jorveza) have been approved by regulatory authorities for EoE treatment of adults in Europe, Canada, and Australia, but not in the USA. Jorveza, as compared to placebo, is effective in inducing and maintaining histologic and clinical remission over time. An orodispersible budesonide suspension (BOS, Eohilia) was recently approved in the USA as induction treatment (12 weeks) in adolescents of at least 11 years and adults with active EoE. Before the approval of Jorveza and Eohilia, several investigator-initiated randomized controlled clinical studies evaluated esophagus-targeted formulations of either budesonide or fluticasone to treat pediatric and adult EoE patients. These drugs were generally efficacious in inducing and maintaining histological and clinical remission. Proton-pump inhibitors (PPIs) are used off-label for EoE treatment of pediatric and adult EoE patients given that they are able to induce histologic and clinical remission. However, when compared to the moderate certainty of evidence with regard to the failure to achieve histologic remission with swallowed topical corticosteroids, the certainty of evidence for PPIs is very low with very inconsistent results in absolute terms. Dupilumab (Dupixent), a monoclonal antibody targeted against IL-4 and IL-13, was approved by regulatory authorities in the USA, Europe, Canada, but not yet Australia. In Europe, including Switzerland, Dupixent is approved to treat EoE patients of at least 12 years of age with at least 40 kg body weight if they are either unresponsive or intolerant to or not candidates for conventional EoE therapies. Due to lack of efficacy or unfavorable safety profile, the following drugs are not recommended for EoE treatment: systemic steroids, sodium cromoglycate, montelukast, azathioprine, TNF-antagonists (e.g., infliximab), vedolizumab (mAb against α4β7), benralizumab (mAb against IL-5 receptor), mepolizumab (mAb against IL-5), reslizumab (mAb against IL-5), omalizumab (mAb against IgE), and lirentelimab (mAb against Siglec-8).

Key Messages: Long-term effectiveness and safety data on different drugs are currently sparse. Concerted efforts of different stakeholders will be necessary to continue the endeavor of providing our patients with much-needed therapies.

References

Spergel J, Rothenberg M, Collins M, Furuta G, Markowitz J, Fuchs 3rd G . Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2011; 129(2):456-63, 463.e1-3. DOI: 10.1016/j.jaci.2011.11.044. View

Molina-Infante J, Rodriguez-Sanchez J, Martinek J, Van Rhijn B, Krajciova J, Rivas M . Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis. Am J Gastroenterol. 2015; 110(11):1567-75. DOI: 10.1038/ajg.2015.314. View

Golekoh M, Hornung L, Mukkada V, Khoury J, Putnam P, Backeljauw P . Adrenal Insufficiency after Chronic Swallowed Glucocorticoid Therapy for Eosinophilic Esophagitis. J Pediatr. 2015; 170:240-5. DOI: 10.1016/j.jpeds.2015.11.026. View

Alexander J, Ravi K, Enders F, Geno D, Kryzer L, Mara K . Montelukast Does not Maintain Symptom Remission After Topical Steroid Therapy for Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2016; 15(2):214-221.e2. DOI: 10.1016/j.cgh.2016.09.013. View

Schoepfer A, Gonsalves N, Bussmann C, Conus S, Simon H, Straumann A . Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol. 2009; 105(5):1062-70. DOI: 10.1038/ajg.2009.657. View

Straumann A, Conus S, Degen L, Frei C, Bussmann C, Beglinger C . Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2011; 9(5):400-9.e1. DOI: 10.1016/j.cgh.2011.01.017. View

Lucendo A, Miehlke S, Schlag C, Vieth M, von Arnim U, Molina-Infante J . Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial. Gastroenterology. 2019; 157(1):74-86.e15. DOI: 10.1053/j.gastro.2019.03.025. View

Giriens B, Yan P, Safroneeva E, Zwahlen M, Reinhard A, Nydegger A . Escalating incidence of eosinophilic esophagitis in Canton of Vaud, Switzerland, 1993-2013: a population-based study. Allergy. 2015; 70(12):1633-9. DOI: 10.1111/all.12733. View

Lucendo A, Molina-Infante J, Arias A, von Arnim U, Bredenoord A, Bussmann C . Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017; 5(3):335-358. PMC: 5415218. DOI: 10.1177/2050640616689525. View

10.

Netzer P, Gschossmann J, Straumann A, Sendensky A, Weimann R, Schoepfer A . Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur J Gastroenterol Hepatol. 2007; 19(10):865-9. DOI: 10.1097/MEG.0b013e32825a6ab4. View

11.

Stumphy J, Al-Zubeidi D, Guerin L, Mitros F, Rahhal R . Observations on use of montelukast in pediatric eosinophilic esophagitis: insights for the future. Dis Esophagus. 2010; 24(4):229-34. DOI: 10.1111/j.1442-2050.2010.01134.x. View

12.

Spechler S, Genta R, Souza R . Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol. 2007; 102(6):1301-6. DOI: 10.1111/j.1572-0241.2007.01179.x. View

13.

Hirano I, Collins M, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer A . RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. Gastroenterology. 2018; 156(3):592-603.e10. DOI: 10.1053/j.gastro.2018.10.051. View

14.

Nhu Q, Chiao H, Moawad F, Bao F, Konijeti G . The Anti-α4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: a Novel Clinical Observation. Am J Gastroenterol. 2018; 113(8):1261-1263. DOI: 10.1038/s41395-018-0145-1. View

15.

Cheng E, Zhang X, Huo X, Yu C, Zhang Q, Wang D . Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut. 2012; 62(6):824-32. PMC: 3552049. DOI: 10.1136/gutjnl-2012-302250. View

16.

Remedios M, Campbell C, Jones D, Kerlin P . Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc. 2005; 63(1):3-12. DOI: 10.1016/j.gie.2005.07.049. View

17.

Visaggi P, Barberio B, Del Corso G, De Bortoli N, Black C, Ford A . Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis. Gut. 2023; 72(11):2019-2030. DOI: 10.1136/gutjnl-2023-329873. View

18.

Attwood S, Lewis C, Bronder C, Morris C, Armstrong G, Whittam J . Eosinophilic oesophagitis: a novel treatment using Montelukast. Gut. 2003; 52(2):181-5. PMC: 1774975. DOI: 10.1136/gut.52.2.181. View

19.

Sawas T, Dhalla S, Sayyar M, Pasricha P, Hernaez R . Systematic review with meta-analysis: pharmacological interventions for eosinophilic oesophagitis. Aliment Pharmacol Ther. 2015; 41(9):797-806. DOI: 10.1111/apt.13147. View

20.

Schoepfer A, Straumann A, Safroneeva E . Pharmacologic Treatment of Eosinophilic Esophagitis: An Update. Gastrointest Endosc Clin N Am. 2017; 28(1):77-88. DOI: 10.1016/j.giec.2017.07.007. View